Loading
Atebimetinib is an experimental small-molecule drug from Immuneering in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at MEK1/2.
Atebimetinib is a small-molecule drug developed by Immuneering. Its target is MEK1/2 (the sponsor names MEK). The sponsor states: Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), in pancreatic ductal adenocarcinoma. The largest, NCT07562152, plans to enrol 510 participants with primary completion expected 2028-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Oral, once-daily 'Deep Cyclic Inhibitor' of MEK that pulses target inhibition rather than suppressing it continuously. Connects to MEK1/2.
1.Atebimetinib slips into a pocket on MEK1/2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Atebimetinib" OR ABSTRACT:"Atebimetinib") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Atebimetinib, not a curated reading list.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.